NASDAQ:INZY Inozyme Pharma (INZY) Stock Forecast, Price & News $6.43 +0.06 (+0.94%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$6.31▼$6.5850-Day Range$3.70▼$6.7452-Week Range$0.99▼$7.24Volume567,612 shsAverage Volume1.19 million shsMarket Capitalization$283.11 millionP/E RatioN/ADividend YieldN/APrice Target$16.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Inozyme Pharma MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside148.8% Upside$16.00 Price TargetShort InterestHealthy1.73% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$3.17 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.70) to ($1.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.24 out of 5 starsMedical Sector542nd out of 983 stocksPharmaceutical Preparations Industry265th out of 486 stocks 3.5 Analyst's Opinion Consensus RatingInozyme Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.00, Inozyme Pharma has a forecasted upside of 148.8% from its current price of $6.43.Amount of Analyst CoverageInozyme Pharma has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.73% of the float of Inozyme Pharma has been sold short.Short Interest Ratio / Days to CoverInozyme Pharma has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldInozyme Pharma does not currently pay a dividend.Dividend GrowthInozyme Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INZY. Previous Next 2.1 News and Social Media Coverage News SentimentInozyme Pharma has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Inozyme Pharma this week, compared to 1 article on an average week.Search InterestOnly 10 people have searched for INZY on MarketBeat in the last 30 days. This is a decrease of -74% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Inozyme Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inozyme Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $3,174,032.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 9.72% of the stock of Inozyme Pharma is held by insiders.Percentage Held by Institutions76.35% of the stock of Inozyme Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Inozyme Pharma are expected to grow in the coming year, from ($1.70) to ($1.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inozyme Pharma is -4.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inozyme Pharma is -4.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInozyme Pharma has a P/B Ratio of 2.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Inozyme Pharma (NASDAQ:INZY) StockInozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.Read More Receive INZY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inozyme Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address INZY Stock News HeadlinesJune 2, 2023 | finance.yahoo.comInozyme Pharma to Present at the Jefferies Healthcare ConferenceMay 17, 2023 | americanbankingnews.comRobert Lorne Hopfner Buys 219,230 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) StockJune 3, 2023 | Stocks To Trade (Ad)Free SMS Trade Alerts. Up to 15 opportunities a day.Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 16, 2023 | benzinga.comInozyme Pharma Insider Trades Send a SignalMay 14, 2023 | americanbankingnews.comQ2 2023 Earnings Forecast for Inozyme Pharma, Inc. Issued By HC Wainwright (NASDAQ:INZY)May 9, 2023 | finanznachrichten.deInozyme Pharma Inc.: Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business HighlightsMay 9, 2023 | msn.comRecap: Inozyme Pharma Q1 EarningsMay 9, 2023 | finance.yahoo.comInozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business HighlightsJune 3, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 3, 2023 | finance.yahoo.comInozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 22, 2023 | americanbankingnews.comInozyme Pharma's (INZY) Buy Rating Reaffirmed at Needham & Company LLCApril 19, 2023 | msn.comAnalyst Ratings for Inozyme PharmaApril 19, 2023 | msn.comNeedham Reiterates Inozyme Pharma (INZY) Buy RecommendationApril 16, 2023 | finance.yahoo.comA number of insiders bought Inozyme Pharma, Inc. (NASDAQ:INZY) stock last year, which is great news for shareholdersApril 14, 2023 | finance.yahoo.comInozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS)April 11, 2023 | finance.yahoo.comInozyme Pharma to Participate at the 22nd Annual Needham Virtual Healthcare ConferenceApril 7, 2023 | 247wallst.comPivotal bioVenture Partners Fund I Now Owns 7.4% of Inozyme PharmaApril 4, 2023 | finance.yahoo.comInozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Operations OfficerApril 2, 2023 | americanbankingnews.comInsider Buying: Inozyme Pharma, Inc. (NASDAQ:INZY) Director Buys $1,564,447.68 in StockMarch 31, 2023 | americanbankingnews.comInsider Buying: Inozyme Pharma, Inc. (NASDAQ:INZY) Director Buys 51,074 Shares of StockMarch 29, 2023 | benzinga.comInozyme Pharma Inc (INZY) is higher by 32.61% in a Week, Should You Buy?March 29, 2023 | americanbankingnews.comJefferies Financial Group Weighs in on Inozyme Pharma, Inc.'s Q1 2023 Earnings (NASDAQ:INZY)March 28, 2023 | finance.yahoo.comHere's Why Inozyme Pharma Has My AttentionMarch 28, 2023 | americanbankingnews.comQ1 2023 EPS Estimates for Inozyme Pharma, Inc. (NASDAQ:INZY) Increased by AnalystMarch 26, 2023 | americanbankingnews.comAnalysts Offer Predictions for Inozyme Pharma, Inc.'s Q2 2023 Earnings (NASDAQ:INZY)March 24, 2023 | americanbankingnews.comInozyme Pharma (NASDAQ:INZY) Upgraded to "Buy" by Jefferies Financial GroupMarch 24, 2023 | americanbankingnews.comWedbush Reiterates "Outperform" Rating for Inozyme Pharma (NASDAQ:INZY)See More Headlines INZY Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INZY Company Calendar Last Earnings3/22/2023Today6/03/2023Next Earnings (Estimated)8/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INZY CUSIPN/A CIK1693011 Webwww.inozyme.com Phone857-330-4340FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Forecast$16.00 High Stock Price Forecast$23.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+148.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-67,060,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-53.46% Return on Assets-45.28% Debt Debt-to-Equity Ratio0.23 Current Ratio10.66 Quick Ratio10.66 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.35 per share Price / Book2.74Miscellaneous Outstanding Shares44,030,000Free Float39,755,000Market Cap$283.11 million OptionableNot Optionable Beta1.08 Key ExecutivesMr. Axel Bolte M.B.A. (Age 50)M.Sc., Co-Founder, Pres, CEO & Director Comp: $889.66kMr. Henric Bjorn Bjarke (Age 55)Sr. VP & COO Comp: $597.68kDr. Demetrios Braddock M.D.Ph.D., Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board ObserverMr. Sanjay S. Subramanian M.B.A. (Age 45)M.S., CFO & Principal Accounting Officer Dr. Soojin Kim Ph.D.Sr. VP & Chief Technical Operations OfficerDr. Yves Sabbagh Ph.D.Chairman of Scientific Advisory Board, Sr. VP & Chief Scientific OfficerMr. Stefan RileyDirector of Investor RelationsMs. Gayle GirondaSr. VP & Chief People OfficerDr. David Thompson M.A.M.S., Ph.D., Chief Devel. OfficerMr. Stephen J. Di Palma M.B.A (Age 63)M.B.A., Consultant More ExecutivesKey CompetitorsPDS BiotechnologyNASDAQ:PDSBLianBioNASDAQ:LIANI-MabNASDAQ:IMABEagle PharmaceuticalsNASDAQ:EGRXKaryopharm TherapeuticsNASDAQ:KPTIView All CompetitorsInsiders & InstitutionsSphera Funds Management LTD.Bought 156,800 shares on 5/16/2023Ownership: 4.046%Geode Capital Management LLCBought 8,082 shares on 5/16/2023Ownership: 0.548%State Street CorpBought 21,700 shares on 5/16/2023Ownership: 0.223%Jane Street Group LLCBought 53,525 shares on 5/16/2023Ownership: 0.122%Susquehanna International Group LLPBought 34,500 shares on 5/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions INZY Stock - Frequently Asked Questions Should I buy or sell Inozyme Pharma stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inozyme Pharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INZY shares. View INZY analyst ratings or view top-rated stocks. What is Inozyme Pharma's stock price forecast for 2023? 4 brokerages have issued 1 year price objectives for Inozyme Pharma's shares. Their INZY share price forecasts range from $6.00 to $23.00. On average, they anticipate the company's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 148.8% from the stock's current price. View analysts price targets for INZY or view top-rated stocks among Wall Street analysts. How have INZY shares performed in 2023? Inozyme Pharma's stock was trading at $1.05 on January 1st, 2023. Since then, INZY shares have increased by 512.4% and is now trading at $6.43. View the best growth stocks for 2023 here. When is Inozyme Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023. View our INZY earnings forecast. How were Inozyme Pharma's earnings last quarter? Inozyme Pharma, Inc. (NASDAQ:INZY) posted its quarterly earnings data on Wednesday, March, 22nd. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.04. What other stocks do shareholders of Inozyme Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Inozyme Pharma investors own include Procter & Gamble (PG), Raytheon Technologies (RTX), Cisco Systems (CSCO), CSX (CSX), CVS Health (CVS), Home Depot (HD), Resideo Technologies (REZI), Thermo Fisher Scientific (TMO) and Abbott Laboratories (ABT). When did Inozyme Pharma IPO? (INZY) raised $75 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler served as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Inozyme Pharma's stock symbol? Inozyme Pharma trades on the NASDAQ under the ticker symbol "INZY." Who are Inozyme Pharma's major shareholders? Inozyme Pharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Sphera Funds Management LTD. (4.05%), CHI Advisors LLC (3.07%), Affinity Asset Advisors LLC (1.72%), FMR LLC (1.61%), Samsara BioCapital LLC (1.15%) and BlackRock Inc. (1.03%). Insiders that own company stock include Axel Bolte, Henric Bjorn Bjarke, Holdings A/S Novo, Longitude Capital Partners Iii and Robert Lorne Hopfner. View institutional ownership trends. How do I buy shares of Inozyme Pharma? Shares of INZY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Inozyme Pharma's stock price today? One share of INZY stock can currently be purchased for approximately $6.43. How much money does Inozyme Pharma make? Inozyme Pharma (NASDAQ:INZY) has a market capitalization of $283.11 million. The company earns $-67,060,000.00 in net income (profit) each year or ($1.58) on an earnings per share basis. How can I contact Inozyme Pharma? The official website for the company is www.inozyme.com. The company can be reached via phone at 857-330-4340 or via email at ir@inozyme.com. This page (NASDAQ:INZY) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inozyme Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.